Elemental impurity risk management can help biomanufacturers to maintain regulatory alignment and ensure patient safety.
Monoclonal antibody (mAb) manufacturers struggling with single-use technology (SUT)-derived impurities should use ultrafiltration and diafiltration as the basis of their removal strategies, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback